Cannabinoid Medication for Adults With OCD
Public ClinicalTrials.gov record NCT02911324. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Cannabinoid Medication for Adults With Obsessive-Compulsive Disorder (OCD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
Study identification
- NCT ID
- NCT02911324
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2016
- Primary completion
- Dec 31, 2018
- Completion
- Dec 31, 2018
- Last update posted
- Aug 5, 2020
2016 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| New York State Psychiatric Institute | New York | New York | 10032 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Obsessive-Compulsive Disorder trials
Other public records listing Obsessive-Compulsive Disorder. Sorted by last update posted; newest first. Not a recommendation.
- NCT07774481: Anxiety Skills Study Recruiting
- NCT07728994: SONATA LIFU for OCD Recruiting
- NCT06376734: Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness Recruiting
- NCT03313622: Locating Biomarkers in OCD Through Behavioral Tasks Not yet recruiting
- NCT06173752: Mechanisms of Exposure Therapy for OCD Recruiting
- NCT07158801: Project EMPOWER-OCD Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02911324, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2020 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02911324 live on ClinicalTrials.gov.